BISPECIFIC REAGENTS FOR AIDS THERAPY

Abstract: Bispecific molecules which react both with the high-affinity Fc gamma receptor of human effector cells and with a virus or virus component are disclosed. Binding of the molecules to the Fc receptors found on effector cells is not blocked by human immunoglobulin G. The molecules are useful for targeting human effector cells (e.g. macrophages) against a viral target (e.g. HIV or HIV-infected cell). For this purpose, bispecific molecules can be constructed containing the binding region derived from an anti-Fc gamma receptor antibody and the CD4 molecule or CD4 binding domain of the envelope glycoprotein gp120 of HIV. Alternatively, bispecific antibodies or heteroantibodies can be constructed containing the binding region derived from an anti-Fc receptor antibody and the binding region of a HIV-specific antibody such as anti-gp120 antibody. Targeted effector cells can be used to kill virus by cell mediated antibody dependent cytolysis.

Description: BIi I£IZIC_REAGENTS_FOR_AID _THERAPY ■ _^≤.!___5_££HΣ_: In the absence of an effective vaccine or therapy, the incidence of acquired immune deficiency syndrome (AIDS) in the United States and other countries is likely to increase during the next few years. Preventing infection with the human immunodeficiency virus (HIV) will depend upon education and counselling to prevent transmission among the populations at risk for AIDS . To date, neither active immunization with the HIV envelope glycoprotein gpl20 nor passive immunization with AIDS-immune serum has protected non-human primates from subsequent challenge with AIDS. The prospects for effective immunization against HIV infection are not encouraging at this time . Recently, the initial events in infection of human T lymphocytes, macrophages, and other cells by HIV have been elucidated. These events involve the attachment of the HIV envelope glycoprotein gpl20 to its cellular receptor, CD4. Cells that lack CD4 are not susceptible to HIV infection, but become suscep¬ tible after they are transfected with the CD4 gene and express CD4 on their surfaces. This information has led to studies of the use of recombinant CD4 (rCD4) which might be used therapeutically to block the CD4-binding sites on HIV, preventing it from binding to CD4 on host cells. However, this would provide only a passive blockage of virus infection, and would not lead to active elimination of the virus . A therapeutic approach has been developed to eliminate the virus. This involves linkage of CD4 to the Fc region of human IgG. Capon, D.J. ej: a].. , Nature, 337 , 525 (1989). The Fc region of human IgG is the natural ligand for receptors on monocytic cells. Moreover, in the Fc portion of IgG reside immunoglobulin functions such as Fc receptor binding, protein A binding and complement fixation. These properties of the Fc portion of human immuno¬ globulin are the major mechanisms for elimination of pathogens. Fc activates the complement pathway, resulting in lysis of the pathogen, whereas binding to the Fc cell receptors on effector cells can lead to ingestion of the pathogen by phagocytosis or lysis by killer cells. Nevertheless, the vast amount and diversity of natural antibodies (i.e. non-HIV specific IgG) found in vivo remains a major obstacle to this kind of iri vivo therapy since non-HIV specific IgG would be expected to block binding of the Fc region with Fc receptors. A need exists to develop a therapeutic modality that overcomes these problems. Summary of the Invention This invention pertains to bispecific molecules which can bind a pathogen and which can simul¬ taneously target the pathogen and pathogen-infected cells for ingestion and destruction by effector cells such as monocytes, macrophages, and neutrophils. The bispecific molecules of this invention have a first binding specificity for a pathogen (e.g. virus) and a second binding specificity for the high-af inity Fcγ receptor. The binding specificity for the FC receptor is for a site which is distinct from the ligand binding site for the Fc region of IgG. The bispecific molecules are capable of binding to IgG-occupied receptor of effector cells in the presence of normal serum IgG. For example, if the target pathogen is a virus such as HIV, the targeted viral component can be the envelope glycoprotein gpl20 of HIV. The binding specificity for gρl20 can be provided in several ways. It can be provided by the CD4 molecule of T cells or just the CD4 binding domain thereof. Alternatively, the gpl20 specificity can be provided by a gpl20-specific antibody. The binding specifi¬ city for the high affinity Fc receptor is provided by an antibody which binds to an epitope of the Fc receptor, the binding of which is not blocked by human I G . The bispecific molecules of this invention can be administered alone or they can be pre-attached to effector cells for administration to the patient. They can also be used in conjunction with other molecules. For example, molecules of this invention can be used with cytokines such as interferon-7 which can activate or enhance their therapeutic potential. The effector cells can be obtained from the patient or from other sources so long as the cells are compatible with the patient's immune system. The binding of bispecific molecule to the effector cell results in a targeted effector cell i.e. , an effector cell with attached bispecific antibody or heteroantibody containing antigen binding regions which are specific for a desired pathogen. The targeted effector cells can be used to bring about antibody dependent cell mediated cytolysis (ADCC) and/or phagocytosis of the target cells i.n vivo . Detailed Description of the Invention The bispecific molecules of this invention have at least two distinct binding specificities. The molecules contain a binding specificity for a pathogen such as a virus component, and a binding specificity for the FC7 receptor of effector cells. The Fc-receptor binding specificity is provided by a binding agent which binds to the high affinity (p72) Fc receptor (FcRI) for human IgG without being blocked by human IgG. The preferred FC receptor binding agent is an antibody, antibody fragment, antibody variable region, or genetic construct having the following characteristics: a. it reacts specifically with the high affinity Fc7 receptor; b. it reacts with the receptor through its antigen combining region independent of any Fc portion; c. it reacts with an epitope of FC7 receptor which is distinct from the Fc binding (i.e. ligand binding) site of the receptor; and d. it binds ligand-occupied receptor. The anti-Fc7 receptor antibodies of this invention can be produced as described in U.S. Patent Application Serial Number 151,450; Fanger e_t al. , "Monoclonal Antibodies to Fc Receptors for Immunoglobulin G on Human Mononuclear Phagocytes", the teachings of which are incorporated by reference herein. The binding specificity for the pathogen component can be any binding agent specific for an antigen of the pathogen. For example, if the targeted pathogen is a virus , viral antigens such as those associated with Epstein Barr virus (EBV glycoprotein: M. Mackett and J.R. Arrand, EMBO J_^, 4: 3229-3234 (1985)) ; human Influenza virus (Haemagglutinin: E.B. Stephens et al. , EMBO J. , 5_: 237-245 (1986)); hepatitis B virus (HBV major surface antigen: R.H. Purcell and J.L. Gerin, Am. J. ≤d. Sci. , 270: 395-399 (1975)); and HIV (capsid env glycoproteins : A.S. Fauci, S_cj.e_nc_e, 2_33: 617-622 (1988)) can be used as the source of viral target antigen needed to produce the binding specificity for molecules of this invention. In preferred embodiments for HIV treatment, the HIV component is the envelope glycoprotein gpl20 of HIV, found in the viral envelope and in cells harboring infectious HIV. The bispecific molecules are specific for gpl20 and the HIV-binding agent can be provided by naturally-ocurring or recombinant forms of the CD4 receptor of T cells or by the HIV binding domain of CD4. It is well known that CD4 , expressed on T- lymphocytes , is the receptor for the HIV envelope glycoprotein gpl20. The CD4 protein is also the primary receptor for HIV entry into host cells, and for membrane fusion which contributes to cell-to-cell transmission of HIV and to its cytopathic effects. Maddon, P.J. _ al.. , C e l 1 , 47: 333-348 (1986). Since the CD4 antigen was identified as the cell-surface receptor for HIV, it has been repeatedly shown that soluble forms of CD4 antigen can block the infectivity of the virus. Traunecker, A. et al. , Nature, 331: 84-86 (1988). Soluble CD4 inhibits diverse variants of HIV, indicating that all these viruses may share a relatively conserved CD4-binding region. Soluble CD4 analogs or CD4 fragment with an affinity for gpl20 comparable to that of intact CD4 can be prepared using methods described in the art. e_e_, for example, Berger, E.A. e_t _1 . , Pr££. Nat' 1. Acad. £ci. USA, 5: 2357-2361 (1988); Arthos, J . , et Si- « £^11, 57: 469-481 (1989). Soluble CD4 fragments lack the hydrophobic transmembrane portion or contain only a small fraction of this transmem¬ brane portion. Soluble CD4 fragments and CD4 analogs can be produced by inserting truncated CD4-encoding cDNA into expression vectors. CD4 polypeptide can be produced by such cells and the soluble CD4 can be tested for its ability to bind gpl20 using standard coimmunoprecipitation assays. S. , for example Smith, D.H. e_t a.1 . , Science 233 , 1704-1707 (1987). Alternatively, the HIV binding specificity of the molecules of this invention can be provided by anti-gpl20 antibodies. These antibodies can also be produced by conventional monoclonal antibody method¬ ology, e.g. the standard somatic cell hybridization technique of Kohler and Milstein, Nature, , 255, 495 (1975) , using the gpl20 glycoprotein, or fragments thereof, as the immunogen. In brief, an animal such as a mouse is immunized with gρl20 of HIV. The gpl20 can be purified, or partially purified from viral lysates for this purpose. The purification of gpl20 can be accomplished by affinity chromatography with antibody against gpl20. After immunization, B cells are taken from the immunized animal and then fused with an immortalizing cell such as a myeloma cell. S.ee, for example, M.S.C. Fung e_t al . , Biotechnology, 5 : 940-946 (1987). It will be appreciated that subunits of gpl20 can also be employed as the HIV component to which a binding specificity is provided. For example, antibodies can be prepared against the gp41 transmembrane protein as well as smaller gene products of the envelope gene of HIV. S. , for example, .G. Robey et al, , Science 228, 593-595 (1985). Bispecific molecules of this invention can also be prepared by conjugating a binding specificity for a pathogen (i.e. virus or viral antigen) to an anti-Fc7 receptor (FC7R) gene. Development and cloning of the gene for the binding site of anti-Fc7R, is well within the capabilities of those skilled in the art. This gene could be linked to genes encoding viral receptors such as the CD4 molecule. Such constructs can be used to target viral infectious agents and infected cells through FC7R. The bispecific molecules of this invention can be of several configurations. Bispecific antibodies are single antibodies (or antibody fragments) which have two different antigen binding sites (variable regions). Bispecific antibodies of this invention have one binding site for FC7 receptor and one binding site for a viral epitope. Bispecific antibodies can be produced by chemical techniques (see e.g. , Kranz , D. M. e_t a].. , Proc. Na11. Ac_ad. _£.L - π_SA 78,5807 (1981)) by "polydoma" techniques (see U.S. Patent 4,474,893, to Reading) or by recombinant DNA techniques. Heteroantibodies are two or more antibodies, or antibody binding fragments (Fab) linked together, each antibody or fragment having a different speci¬ ficity. Bivalent heteroantibodies of this invention comprise an antibody (or fragment) specific for FC7 receptor, coupled to an antibody (or fragment) specific for a viral epitope. Heteroantibodies can be prepared by conjugating FC7 receptor antibody with antibody specific for an epitope of the HIV envelope glycoprotein gpl20. A variety of coupling or crosslinking agents can be used to conjugate the antibodies. Examples are protein A, carboiimide, dimaleimide, dithio-bis -nitrobenzoic acid (DTNB) , and N-succinimidyl-3- (2-pyridyldithio) propionate (SPDP) . SPDP and DTNB are the preferred agents; procedures for crosslinking antibodies with these agents are known in the art. £>££ e.g. , Karpovsky, B - it al. , (1984) J. Exp_. Med. 160:1686; Liu, M.A. et al. , (1985) Proc. Nat].. Acad. Sci VSA 2:8648; Segal, D.M. and Perez, P. , U.S. Patent No. 4,676,980 (June 30, 1987); and Brennan, M. Bio ^ echni^ue^ 4:424 (1986) . The bispecific molecules of this invention can also be prepared as recombinant molecules. Con¬ structs can be developed that comprise genes en- coding viral receptors linked to genes encoding the binding site (variable region) of anti-Fc7R anti¬ body. Thus, a recombinant nucleic acid which encodes a molecule having dual specificity can be prepared by linking a gene encoding a receptor for a viral antigen (e.g. a cell-surface receptor such as CD4 which binds to gpl20 on HIV or HIV-infected cells) to the gene encoding either the light or heavy chain variable region of an anti-Fc7R anti¬ body. These genetic constructs, or other constructs linking genes for different viral receptors to the anti-Fc7R antibody gene, can be expressed in suit¬ able host cells . Bispecific molecules of this invention can be administered to target the killing of virus and virally infected cells. The molecules can be given in free form. Alternatively, the molecules can be attached to the surface of effector cells i.n vi πro and the cells can be administered. In each mode the principle is the same; the effector cell is targeted toward the virus . Effector cells for targeting are human leuko¬ cytes, preferably macrophages. Other cells can include onocytes, activated neutrophils , and possibly activated natural killer (NK) cells and eosinophils. Macrophages can be treated with IFN-7 before targeting to increase the number of Fc receptors for attachment of the targeting antibody or heteroantibody. Neutrophils and NK cells can also be activated with IFN-7 in this way. The effector cells may also be activated before targeting by other cytokines such as tumor necrosis factor, lymphotoxin, colony stimulating factor, and interleukin-2. If desired, effector cells for targeting can be obtained from the host to be treated, or any other immunologically-compatible donor . The targeted effector cells can be administered as a suspension of cells in a physiologically acceptable solution. The number of cells adminis- 8 9 tered can be in the order of 10 -10 , but will vary depending on the therapeutic purpose. In general, the amount will be sufficient to obtain localization of the effector cell at the target cell or pathogen, and to effect killing of the cell or pathogen by antibody dependent cell-mediated cytolysis (ADCC) and/or phagocytosis. Routes of administration can also vary. The targeted effector cells could be administered intravenously, intramuscularly, or intraperitoneally. Bispecific molecules of this invention link viral-specific binding agents to FC7R on effector cells in such a way that the large excess of human IgG jLn v^v does not interfere with binding of the molecule to effector cells or interfere with functioning of effector cells. This is possible because the anti-Fc7R component of these molecules binds to FC7R at an epitope outside of its ligand binding domain. Effector cells (i.e. macrophages) targeted in this way can be employed to bring about antibody-dependent cell-mediated killing of HIV or HIV-infected cells. The bispecific molecules of this invention have a potentially long half-life i.11 yL £. This can result from the interaction of these constructs with FC R on all monocytes and macrophages where it might remain for long periods of time, much of it out of circulation, but functionally active throughout the body on all cells of the reticuloendothelial system. Bivalent bispecific molecules of this invention can be more sensitive to triggering than other constructs because of their bivalent nature. This is because internalization of the construct and killing of the targeted infectious agent requires receptor crosslinking. A bivalent bispecific complex will initiate cross -linking more efficiently that a monovalent bispecific construct. Furthermore, the binding avidity of a bivalent bispecific construct is likely to be greater than a monovalent bispecific molecule, and therefore be more effective in clearing HIV and HIV-infected cells. This is an important advantage of a bivalent bispecific molecule. A monovalent molecule comprising, for example, the Fc region of IgG complexed with a viral binding specificity (Capon, D.J. e_t a1 ^ . , sujra) will bind to only one FC7RI molecule since only one of the Fc regions of an antibody can bind to the high-affinity FC7RI receptor. Constructs of this invention having bivalent bispecific or heteroantibody configurations offer an advantage since they can be manipulated to provide greater avidity or triggering capability. The bispecific molecules of this invention are specific for interaction with only FC7RI . Constructs employing the Fc domain of IgG (Capon, D.J. e_t a1. , sujra) interact with all three types of Fc receptor. This lack of specificity may be of considerable disadvantage since FC7RII and FC7RIII are expressed by other cells besides monocytes, such as B-cells, platelets, and placental Ig transfer cells. Thus, there is the possibility that HIV may be introduced through FC7RII and/or FC7RIII into cells that cannot kill but which may harbor the virus. Moreover, FC7RI has been found to be a killing receptor on all cell populations on which it has been found. In contrast, the other two Fc receptors only function as cytotoxic trigger molecules on some of the cells on which they are expressed, and then only under some conditions. Equivalents Those skilled in the art will recognize, or be able to ascertain using no more than routine experi¬ mentation, many equivalents to the specific embodi¬ ments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

Claims: CLAIMS 1. A bispecific molecule having a binding specificity for a pathogen or pathogen component and a binding specificity for the high-affinity FC7 receptor, the binding of which to the FC7 receptor is not blocked by human immunoglobulin G. 2. A bispecific molecule of Claim 1, wherein the pathogen or pathogen component is a virus or viral component. 3. A bispecific molecule of Claim 2, wherein the virus is human immunodeficiency virus (HIV) . 4. A bispecific molecule of Claim 3, wherein the virus component is the envelope glyco- protein gpl20 of HIV or a fragment thereof. 5. A bispecific molecule of Claim 3, wherein the virus component is the envelope glycoprotein gp41 of HIV. 6. A bispecific molecule of Claim 4, wherein the binding specificity for the virus component gpl20 is provided by the CD4 receptor of T-cells or the gpl20 binding domain thereof. 7. A bispecific molecule of Claim 4, wherein the binding specificity for the virus component gpl20 is provided by an gpl20-specific antibody or fragment thereof. 8. A bispecific molecule of Claim 1, which is a bispecific antibody. 9. A bispecific molecule of Claim 1, which is an aggregate of two or more antibodies or fragments thereof. 10. A bispecific molecule of Claim 1 which is a recombinant molecule. 11. A bispecific molecule comprising a specific binding agent for human immunodeficiency virus (HIV) and a specific binding agent for the high affinity Fc7 receptor for IgG on human monocytes, the binding site for the agent on the high-affinity FC7 receptor being distinct from the ligand binding site of the receptor for Fc. 12. A bispecific molecule of Claim 11, wherein the specific binding agent for HIV binds to the envelope glycoprotein gpl20 or a fragment thereof. 13. A bispecific molecule of Claim 11, wherein the specific binding agent for HIV binds to the envelope glycoprotein gρ41 of HIV. 14. A bispecific molecule of Claim 11, wherein the specific binding agent is the CD4 receptor of T-cells . 15. A bispecific molecule of Claim 11, wherein the specific binding agent is anti-gpl20 antibody. 16. A bispecific reagent, comprising a CD4 receptor linked to an antibody or fragment thereof specific for an epitope of the high affinity Fc7 receptor, the epitope being outside of the ligand binding domain for Fc of the receptor and the binding of which to the Fc receptor is not blocked by human immunoglobulin G. 17. A heteroantibody, comprising: a. an antibody or antibody binding fragment specific for the envelope gpl20 glycoprotein of the HIV virus; and b. an antibody or antibody binding fragment specific for the high-affinity FC7 receptor for IgG on human effector cells, the binding of which to the human Fc receptor of the effector cells is not blocked by human immunoglobulin G. 18. A heteroantibody of Claim 17, wherein the effector cell is selected from the group con- sisting of monocytes, macrophages, neutrophils and eosinphils. 19. A target-specific effector cell, comprising: a. an effector cell expressing high affinity receptor for the Fc portion of IgG; and b. a bispecific molecule bound to an epitope of the Fc receptor of the effector cell that is outside of the ligand binding domain of the receptor, the molecule comprising: (i) at least one binding specificity for a virus or virus component; and (ii) at least one binding specificity for the high-affinity FC7 receptor, the binding of which to the Fc receptor of the effector cell is not blocked by human immunoglobulin G. 20. A target-specific effector cell of Claim 19, wherein the effector cell is a human monocyte or acrophage . 21. A target-specific effector cell of Claim 19, wherein the virus is human immunodeficiency virus (HIV) . 22. A target specific effector cell of Claim 19, wherein the virus component is envelope glycoprotein gpl20 of HIV. 23. A target specific effector cell of Claim 19, wherein the virus component is the envelope glycoprotein gp41 of HIV. 24. A target specific effector cell of Claim 22, wherein the binding specificity for a virus component is provided by the CD4 region of T-cells or the gpl20 binding domain thereof. 25. A target-specific effector cell of Claim 22 wherein the binding specificity for a virus component is provided by an gpl20-specific antibody or fragment thereof. 26. A target-specific effector cell of Claim 19, wherein the bispecific molecule is a bispecific antibody. 27. A target-specific effector cell of Claim 19, wherein the bispecific molecule is an aggregate of two antibodies or fragments thereof. 28. A method of treating viral infection, comprising administering to a patient afflicted with a viral infection, a therapeutic amount of targeted effector cells , each targeted effector cell comprising: a. an effector cell expressing receptor for the Fc portion of IgG complexed with a; b. bispecific molecule bound to the Fc receptor of the effector cell, the bispecific molecule comprising: (i) at least one binding specificity for a virus or virus component; and (ii) at least one binding specificity for the high-affinity FC7 receptor on the effector cell, the binding of which to the Fc receptor of the effector cell is not blocked by human immunoglobulin G and which binds to an epitope on the Fc receptor of the effector cell that is outside of its ligand binding domain. ~ 29. A method of Claim 28, wherein the virus is the human immunodeficiency virus (HIV) . 30. A method of Claim 28, wherein the virus component is the envelope glycoprotein gρl20 of HIV. 0 31. A method of Claim 28, wherein the virus component is the envelope glycoprotein gp41 of HIV. 32. A method of Claim 30, wherein the binding specificity for the virus component is provided 5 by the CD4 receptor of T-cells or the gpl20 binding domain thereof. 33. A method of Claim 30, wherein the binding specificity for the virus component is provided by an gpl20-specific antibody or fragment thereof. 34. A method of Claim 28, wherein the bispecific molecule is a bispecific antibody. 35. A method of Claim 28, wherein the bispecific molecule is an aggregate of two or more antibodies or fragments thereof. 36. A method of Claim 28, wherein the effector cell is a human monocyte or macrophage. 37. A method of treating viral infection in a patient, comprising administering to a patient afflicted with a viral infection a therapeutic amount of a bispecific molecule, the molecule comprising: (i) at least one binding specificity for a virus or virus component; and (ii) at least one binding specificity for the high-affinity FC7 receptor on the effector cell, the binding of which to the Fc receptor of the effector cell is not blocked by human immuno¬ globulin G and which binds to an epi- tope on the Fc receptor of the effector cell that is outside of its ligand binding domain. 38. A method of Claim 37, wherein the virus is the human immunodeficiency virus (HIV) . 39. A method of Claim 37, wherein the virus component is the envelope glycoprotein gpl20 of HIV. 40. A method of Claim 37, wherein the virus component is the envelope glycoprotein gp41 of HIV. 41. A method of Claim 39, wherein the binding specificity for the virus component is provided by the CD4 receptor of T-cells or the gpl20 binding domain thereof. 42. A method of Claim 39, wherein the binding specificity for the virus component is provided by an gpl20-specific antibody or fragment thereof. 43. A method of Claim 37, wherein the bispecific molecule is a bispecific antibody. 44. A method of Claim 37, wherein the bispecific molecule is an aggregate of two or more antibodies or fragments thereof.

Inventors: DINCES NATHAN B, FANGER MICHAEL W, GUYRE PAUL M, DINCES, NATHAN, B., FANGER, MICHAEL, W., GUYRE, PAUL, M.
Applicants: MEDAREX INC, MEDAREX, INC.
Application year: 1990
Main classification: C12N5
IPC codes: A61K38, A61K47, C07K14, C07K16